Download PDF
Thromb Haemost 1997; 78(01): 042-046
DOI: 10.1055/s-0038-1657498
Thrombopoietin
Schattauer GmbH Stuttgart

Clinical Studies with Megakaryocyte Growth and Development Factor (Mpl-ligand)

C Glenn Begley
The Walter and Eliza Hall Institute of Medical Research, Rotary Bone Marrow Research Laboratories, PO Royal Melbourne Hospital, Victoria, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Basser R, Clarke K, Fox R, Green M, Cebon J, Marty J, Menchaca D, Tomita D, Begley CG. Randomized double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy-early results. Blood 1995; 86 (Suppl. 01) 257a
    PubMedGoogle Scholar
  • 2 Rasko JEJ, Basser R, O’Malley CJ, Mansfield R, Boyd J, Grigg A, McGrath K, Marty J, Sheridan WP, Hussein S, Bemdt MC, Begley CG. In vitro results from a phase I randomized, blinded trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF). Blood 1995; 86 (Suppl. 01) 497a
    PubMedGoogle Scholar
  • 3 Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279-1281
    CrossrefPubMedGoogle Scholar
  • 4 O’Malley CJ, Rasko JJ, Basser RL, McGrath KM, Hopkins W, Grigg AP, Cebon J, Cohen B, Green MD, Fox RM, Bemdt MC, Begley CG. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88: 3288-3298
    PubMedGoogle Scholar
  • 5 Begley CG, Basser R, Clarke K, Rasko J, Green M, Grigg AP, Cebon J, Marty J, Menchaca D, Tomita D, Fox RM. Randomised, double-blind placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor administered to patients with advanced cancer after chemotherapy. Proc Am Soc Clin One 1996; 15: 719a
    PubMedGoogle Scholar
  • 6 Fanucchi M, Glaspy J, Crawford J, Ozer H, Giflin R, Tomita D, Menchaca D, Harker L. Safety and biological effects of pegylated megakaryocyte growth and development factor in lung cancer patients receiving carboplatin and paclitaxel: randomised, placebo-controlled phase I study. Proc Am Soc Clin One 1996; 15: 720a
    PubMedGoogle Scholar
  • 7 Vadhan-Raj S, Burris H, Benjamin RS, Patel S, Johnston T, Heilman S, Cohen R, Watanabe B, Von Hoff D. Single-dose therapy with recombinant human thrombopoietin (rhTPO) in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin One 1996; 15: 2010a
    PubMedGoogle Scholar
  • 8 deBoer R, Fox S, Hopkins W, Casper L, Cheung E, Roskos L, Basser RL, Cebon J. Pharmacodynamics of pegylated megakaryocyte growth & development factor from a phase I study: effects of platelet count on serum levels & clearance. Exp Hematol 1996; 24: 744a
    PubMedGoogle Scholar
  • 9 Basser RL, Rasko JEJ, Clarke K, Green M, Cebon J, Grigg A, Bemdt M, Zalcberg J, Marty J, Menchaca D, Tomita D, Fox R, Begley CG. Pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) enhances the mobilisation of peripheral blood progenitor cells (PBPC) by chemotherapy and filgrastim. Blood 1996; 88 (Suppl. 01) 641a
    PubMedGoogle Scholar
  • 10 Reddy SP, Bueso-Ramos C, Bioko I, Hittelman WN, Vadhan-Raj S. Effects of recombinant human thrombopoietin (rhTPO) on bone marrow megakaryocytes in humans. Blood 1996; 88 (Suppl. 01) 61a
    PubMedGoogle Scholar
  • 11 Murray LJ, Luens KM, Bruno E, Estrada MF, Cohen RL, Heilman SD. Effects of thrombopoietin on megkaryocytes and progenitor cell populations in bone marrow and peripheral blood of sarcoma patients. Blood 1996; 88 (Suppl. 01) 351a
    PubMedGoogle Scholar
  • 12 Bloedow D, Vadhan-Raj S, Paton V, Johnston T, Yang T, Senn T, Ashby M, Sims P. Pharmacokinetics of recombinant human thrombopoietin (rhTPO) after intravenous administration in cancer patients. Blood 1996; 88 (Suppl. 01) 351a
    PubMedGoogle Scholar
  • 13 Vadhan-Raj S, Patel S, Broxmeyer HE, Bueso-Ramso C, Reddy SP, Papadopolous N, Burgess A, Johnston T, Yang T, Paton V, Heilman S, Benjamin RS. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide(I). Blood 1996; 88 (Suppl. 01) 448a
    PubMedGoogle Scholar
  • 14 Archimbaud E, Ottmann O, Liu Yin JA, Lechner K, Dombret H, Sanz MA, Herrmann F, Grass H, Fenaux P, Ganser A, Heil G, Kanz L, Brugger W, Sims T, Olsen K, Hoelzer D. A randomised, double-blind placebo-controlled study using a PEG-rHuMDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia: early results. Blood 1996; 88 (Suppl. 01) 447a
    PubMedGoogle Scholar
  • 15 Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O’Bryne J, Menchaca D, Sheridan WP, Fox RM, Begley CG. Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997. (in press)
    Google Scholar
  • 16 Kaushansky K, and Begley CG. Thrombopoietin: Basic biology and clinical effects. In Hematopoietic Stem Cell Therapy. Eds Ho AD, Champlin RE. Cambridge University Press; 1997. in press
    Google Scholar
  • 17 Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, Bailey MC, Papayannopoulou T, Forstrom JW, Sprugel KH. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J.Clin Invest 1995; 96: 1683-1687
    CrossrefPubMedGoogle Scholar
  • 18 Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, Sprugel KH. Thrombopoietin accelerates platelet, red blood cell and neutrophil recovery in myelosupressed mice, Exp. Hematol 1996; 24: 1238-1246
    PubMedGoogle Scholar
  • 19 Ulich TR, del Casillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WP, Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971-976
    PubMedGoogle Scholar
  • 20 Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86: 54-59
    PubMedGoogle Scholar
  • 21 Harker LA. Kinetics of thrombopoiesis. J Clin Invest 1968; 47: 458-465
    CrossrefPubMedGoogle Scholar
  • 22 Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, Williamson DJ, Wong CG, Clark SC, Wang EA. Biological properties in vitro of a recombinant human granulocyte-macrophage colony stimulating factor. Blood 1986; 67: 37-45
    PubMedGoogle Scholar
  • 23 Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ. Purified colony stimulating factors enhance the survival in vitro of mature human neutrophils and eosinophils in a lineage-specific manner: A rapid sensitive microassay for colony-stimulating factors. Blood 1986; 68: 162-166
    CrossrefPubMedGoogle Scholar
  • 24 Metcalf D, Begley CG, Williamson DJ, Nice EC, DeLaMarter JF, Merrod JJ, Thatcher D, Schmidz A. Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. ExpHematol 1987; 15: 1-9
    PubMedGoogle Scholar
  • 25 Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, Methis N, Charon M, Nador R, Bettaieb A, Vainchenker W. The mpl receptor is expressed in the megakaryocyte lineage from late progenitors to platelets. Blood 1995; 85: 391-401
    PubMedGoogle Scholar
  • 26 Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-mpl-lig-and, induces tyrosine phosphorylation of Tyk 2, JAK 2, and STAT 3 and enhances agonist-induced aggregation in platelets in vitro. FEBS Letters 1995; 374: 48-52
    CrossrefPubMedGoogle Scholar
  • 27 Rasko JEJ, Basser RL, Boyd J, Mansfield R, O’Malley CJ, Hussein S, Bemdt MC, Clarke K, O’Byrne J, Sheridan WP, Grigg AP, Begley CG. Multilineage mobilisation of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haem. 1997. (in press)
    Google Scholar
  • 28 Begley CG. Human progenitor cell assays. In ‘Cell Therapy. Stem cell transplantation, gene therapy, and immunotherapy’. Ed’s Morstyn G, and Sheridan W. Cambridge University Press; 1996. pp 59-74
    Google Scholar
  • 29 Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte-colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081
    PubMedGoogle Scholar
  • 30 Rasko JEJ, O’Flaherty E, Begley CG. mpl-ligand (MGDF) alone and in combination with SCF promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/ macrophage progenitors. Stem Cells 1997; 15: 33-42
    CrossrefPubMedGoogle Scholar
  • 31 Deluca E, Sheridan WP, Watson D, Szer J, Begley CG. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. B J Cancer 1992; 66: 893-899
    CrossrefPubMedGoogle Scholar
  • 32 Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath K, Morstyn G, Fox FM. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339: 640-644
    CrossrefPubMedGoogle Scholar